← Human Trials & Peer-Reviewed Studies
Two years of replacement therapy in adults with growth hormone deficiency.
Plain-language guide to PMID 9404448 (1997): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 148 patients.
Key Facts
- PMID
- 9404448
- Journal
- Clinical endocrinology
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Verhelst J et al. (13 authors)
- DOI
- 10.1046/j.1365-2265.1997.3041112.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Who Took Part
The abstract describes 148 patients taking part.
The age groups tagged for this paper are adults, both men and women.
At the same time patients had a full clinical examination and blood was sampled for glucose, HbA1c, IGF-1, creatinine, full blood count, thyroid hormones and liver function tests.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.
Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.
Every 3-6 months body composition was measured using body impedance analysis and general well being was assessed using the Nottingham Health Profile (NHP) and social self-reporting questionnaire.
What Was Measured
Topics PubMed links to this paper include Body Composition, Body Water, Electric Impedance, Growth Hormone, Human Growth Hormone, Insulin-Like Growth Factor I and Recombinant Proteins.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 148 patients.
Its findings take up roughly 16 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1997 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.